Study Evaluating Prevenar Immunogenicity in High Risk Children

Phase 4 Completed 160 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupOpen-labelPrevention

Summary

To determine immunogenicity of the heptavalent CRM197 pneumococcal conjugate in children with immunodeficiency condition. To evaluate tolerability of Prevenar® in that population.

Timeline

Start: 2002-11
Primary completion: —
Completion: 2007-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Prevnar 13	Vaccine	—	—

Indications

No indication recorded.